Structural features of subtype-selective EP receptor modulators
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Prostaglandin E2 is a potent endogenous molecule that binds to four different G-protein-coupled receptors: EP1-4. Each of these receptors is a valuable drug target, with distinct tissue localisation and signalling pathways. We review the structural features of EP modulators required for subtype-selective activity, as well as the structural requirements for improved pharmacokinetic parameters. Novel EP receptor subtype selective agonists and antagonists appear to be valuable drug candidates in the therapy of many pathophysiological states, including ulcerative colitis, glaucoma, bone healing, B cell lymphoma, neurological diseases, among others, which have been studied in vitro, in vivo and in early phase clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prostanoid Receptors: Subtypes and Signaling
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.661 · Cited by 1,011
Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3
Ushikubi, F., Segi, E., Sugimoto, Y., Murata, T., Matsuoka, T., Kobayashi, T., Hizaki, H., Tuboi, K., Katsuyama, M., Ichikawa, A., et al. (1998) · Nature · doi:10.1038/26233 · Cited by 677
Prostaglandin E 2 induces fibroblast apoptosis by modulating multiple survival pathways
Huang, S. K., White, E. S., Wettlaufer, S. H., Grifka, H., Hogaboam, C. M., Thannickal, V. J., Horowitz, J. C., & Peters-Golden, M. (2009) · The FASEB Journal · doi:10.1096/fj.08-128801 · Cited by 147
Tanaka, M., Sakai, A., Uchida, S., Tanaka, S., Nagashima, M., Katayama, T., Yamaguchi, K., & Nakamura, T. (2004) · Bone · doi:10.1016/j.bone.2004.01.002 · Cited by 107
Cited by
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P., Huang, S. C.-C., Fendt, S.-M., & Ho, P.-C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 733
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer
Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012798 · Cited by 112
“Grapiprant is the most advanced EP4 antagonist (phase II) for the treatment of advanced solid tumors; however, its unsatisfactory pharmacokinetic profiles may hinder its clinical efficacy (Markovic et al, 2017).”
BackgroundRieg, A. D., Suleiman, S., Anker, C., Verjans, E., Rossaint, R., Uhlig, S., & Martin, C. (2018) · Respiratory Research · doi:10.1186/s12931-018-0829-5 · Cited by 59
“Moreover, EP4-receptors also couple to Gαi representing the counter player of Gαs [25, 88].”
BackgroundInfluentialLiu, N., Tang, J., Xue, Y., Mok, V., Zhang, M., Ren, X., Wang, Y., & Fu, J. (2022) · Aging and disease · doi:10.14336/ad.2021.0627 · Cited by 15
Metadata
- Authors
- Markovič, T., Jakopin, Ž., Dolenc, M. S., & Mlinarič-Raščan, I.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 22
- Issue
- 1
- Pages
- 57-71
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2508342609
- Cited by
- 159
- References
- 4
- FWCI
- 11.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structural features of subtype-selective EP receptor modulators. https://app.cochat.ai/papers/10.1016/j.drudis.2016.08.003
- The paper
- Markovič, T., Jakopin, Ž., Dolenc, M. S., & Mlinarič-Raščan, I. (2017). Structural features of subtype-selective EP receptor modulators. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2016.08.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.